You Have Been Invited!
Luke Johnson, MD
Luke Johnson is a pediatric dermatologist by training who sees both children and adults. He is an assistant professor in the University of Utah Department of Dermatology with a keen interest in medical education. He is also interested in technology and multimedia; he co-hosts Dermasphere, a biweekly podcast about recent dermatology research. (www.dermaspherepodcast.com)
Chronic Spontaneous Urticaria in the Dermatology and Allergy Practice: From Guidelines to New Frontiers
Chronic spontaneous urticaria (CSU) is a common, chronic inflammatory skin disease significantly impacting patients' quality of life and associated with substantial healthcare costs. While effective management strategies are available, many patients experience diagnostic delays and suboptimal treatment, underscoring an urgent need for refined diagnostic strategies, better implementation of current therapies, and improved clinician awareness of emerging treatments. This educational initiative will enhance management and ultimately improve the outcomes for patients with CSU.
Itinerary
CSU Fundamentals
Answer the following questions to assess your knowledge on CSU management.
This module covers CSU diagnosis guidelines, including differentiation from other disorders and appropriate use of laboratory tests and imaging. This module also addresses CSU endotypes and biomarkers for individualizing diagnostic strategies and predicting therapy response.
This module explores current CSU treatment algorithms, covering appropriate use of guideline-recommended therapies such as second-generation antihistamines and omalizumab. The module also addresses special populations, patient-centered care, and shared decision-making.
This module explores novel CSU therapies, including BTK and IL-4/13 inhibitors, and mast cell-targeting agents. We will assess their efficacy and safety to determine their role in addressing unmet needs for patients with uncontrolled CSU.
Now that you have reviewed the self-study modules, answer the following questions to assess your knowledge of CSU management.
This activity features a 38-year-old woman with CSU refractory to antihistamines. The patient case activity highlights the challenges of diagnostic delays, treatment escalation, and factors influencing therapeutic choices.
Review of CSU Fundamentals and Patient Case
Latest CSU Developments
CSU Highlights from Fall Clinical Dermatology Conference and ACAAI Annual Scientific Meeting (November/December 2025)
CSU Highlights from the AAAAI Annual Meeting (March 2026)
CSU Highlights from the AAD Annual Meeting (April 2026)
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with CSU.
